Benefit–risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment

OBJECTIVES: To conduct the benefit–risk assessment of 3-hydroxy-3-methyl-glutaryl (HMG) coenzyme A reductase inhibitors (statins) using a discrete choice experiment, based on 3 major stakeholders’ perspectives including patients, experts and policymakers in Thailand. DESIGN: A discrete choice experi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanishayakorn, Tanatape, Sornlertlumvanich, Korn, Ngorsuraches, Surachat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769438/
https://www.ncbi.nlm.nih.gov/pubmed/26916689
http://dx.doi.org/10.1136/bmjopen-2015-009387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769438/
https://www.ncbi.nlm.nih.gov/pubmed/26916689
http://dx.doi.org/10.1136/bmjopen-2015-009387

Ejemplares similares